Navigation Links
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
Date:8/6/2009

s release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

    SEQUENOM, Inc.
    Condensed Consolidated Financial Statements - June 2009
    (in thousands, except per share data)

    Consolidated Summary of Operations - Q2 to June & YTD June

                             ---------------------      --------------------
                               Three months ended         Six months ended
                                    June 30,                  June 30,
                               2009          2008         2009         2008
                               ====          ====         ====         ====
                           (unaudited)   (unaudited)  (unaudited)  (unaudited)
    Product revenues:
      Consumables             $5,196        $4,940       $9,918       $9,600
      System related           3,295         6,640        6,421       11,152
      Services                   677         1,190        1,514        2,548
      Research and other           -            75            3          120
                                 ---            --          ---          ---
          Total revenues       9,168        12,845       17,856       23,420

    Costs and expenses:
      Costs of product
       and service revenues    3,126         5,462        6,550       10,133
      Research and development
       expenses               10,226         6,413       19,006       11,298
      Selling and marketing
       expenses                6,934         6,326       14,253       12,139
      General and
       administrative
       expenses                8,196         4,252       15,138        7,622
      Restructuring            1,002             -        1,002    
'/>"/>
SOURCE SEQUENOM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. SEQUENOM Announces Launch of MassARRAY Compact 96 System
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
5. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
8. PDI Reports 2009 Second Quarter Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. NxStage Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Board: SYMD), a biomaterials company engaged in the development,and ... Robert P. Hickey, President and CEO, will present at,the ... 2007 at,5:05 PM, EDT, at the New York Palace ... company overview. The presentation will be available via ...
... the Delft University of Technologys Kavli Institute of Nanoscience ... have succeeded in controlling the spin of a single ... way for a much simpler realization of the building ... will publish their work in Science Express on Thursday ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a biopharmaceutical ... medicines in the areas of hepatitis C and,oncology, ... quarter ended,September 30, 2007 and operational highlights. ... transition for Anadys,",said Steve Worland, Ph.D., President and ...
Cached Biology Technology:Delft University of Technology rotates electron spin with electric field 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 8Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 9
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... May 30, 2011 Reportlinker.com announces that ... in its catalogue: Enzymes ... http://www.reportlinker.com/p0535955/Enzymes-in-Drug-Manufacturing.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical Biocatalysis in pharmaceutical ... enzyme and genomics technologies that are increasing ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
... drugs to combat or cure human disease often involves a ... clearly into a living mouse,s innards has real value. ... interior of laboratory mice, the view becomes so murky several ... divining the future from the rodent,s entrails than they do ...
Cached Biology News:Reportlinker Adds Enzymes in Drug Manufacturing 2Reportlinker Adds Enzymes in Drug Manufacturing 3Reportlinker Adds Enzymes in Drug Manufacturing 4Reportlinker Adds Enzymes in Drug Manufacturing 5Reportlinker Adds Enzymes in Drug Manufacturing 6Novel pathway regulating angiogenesis may fight retinal disease, cancers 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 3
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
...
Biology Products: